General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
CVM Stock Earnings: CEL-SCI Reported Results for Q2 2024 | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-16 | 2024-03 | -0.14 | -0.14 | N/A | N/A |
2024-02-14 | 2023-12 | 0 | -0.14 | N/A | N/A |
2023-12-22 | 2023-09 | -0.16 | -0.16 | N/A | N/A |
2023-08-11 | 2023-06 | -0.17 | -0.19 | -0.02 | -11.76% |
2023-05-12 | 2023-03 | 0 | -0.19 | N/A | N/A |
2023-02-14 | 2022-12 | 0 | -0.18 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-07-11 | EF Hutton | Upgrade | Buy | Buy |
2023-03-08 | EF Hutton | Upgrade | Buy | |
2022-12-28 | EF Hutton | Upgrade | Buy | |
2022-04-06 | EF Hutton | Upgrade | Buy | |
2020-01-12 | HC Wainwright & Co. | Upgrade | Buy | |
2013-02-19 | Taglich Brothers | Upgrade | Speculative Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-07-05 | BAILLAVOINE BRUNO JEAN-MARIE | Director | 5.97K | Purchase |
2021-04-21 | CIPRIANO JOHN S | Officer | 63.11K | Sale |
2016-08-30 | DE CLARA MAXIMILIAN D | Former | 675.12K | Stock Award(Grant) |
2024-05-07 | KERSTEN GEERT R | Chief Executive Officer | 1.20M | Purchase |
2010-03-17 | KINSOLVING C RICHARD | Director | 302.25K | Sale |
2024-05-07 | PRICHEP PATRICIA B | Officer | 232.33K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 1.90M | 4.58M | 4.02% |
2023-06-29 | Blackrock Inc. | 753.70K | 1.82M | 1.59% |
2023-06-29 | D.A. Davidson & Co. | 529.19K | 1.28M | 1.12% |
2023-06-29 | Geode Capital Management, LLC | 423.50K | 1.02M | 0.90% |
2023-06-29 | Osaic Holdings Inc | 386.02K | 930.30K | 0.82% |
2023-06-29 | Susquehanna International Group, LLP | 180.09K | 434.02K | 0.38% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.23M | 2.97M | 2.61% |
2023-06-29 | Vanguard Extended Market Index Fund | 591.63K | 1.43M | 1.25% |
2023-05-30 | Fidelity Extended Market Index Fund | 209.39K | 502.53K | 0.44% |
2023-06-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 83.60K | 201.48K | 0.18% |
2023-08-30 | iShares Micro Cap ETF | 80.75K | 112.24K | 0.17% |
2023-05-30 | Fidelity Total Market Index Fund | 62.12K | 149.10K | 0.13% |
Dividend | Date |
---|---|
0.25 | 1996-08-28 |
Split | Date |
---|---|
1 : 25 | 2017-06-15 |
0.1 : 1 | 2013-09-25 |
1 : 10 | 1995-05-01 |
What we have with CVM is an inept (or corrupt) CEO who cannot navigate the regulatory agencies (remember, MK has been in trials/development for over 30 years) coupled with a corrupt FDA that is totally beholding to big pharma and basically does its bidding. CVM will be bled dry and acquired by a big player at a huge discount to the $150-$200/s CVM would command with approval.
I will repost this for the umpteenth time. The original study DID show - with no concerns - that MK had ZERO TOXICITY! With that established, there is no reason for another trial. The FDA can - and should - give some type of conditional improvement. Phase III trials have 2 purposes - to show that a drug is effective (40% increased 5 year survival seems to do that) and to uncover any side effects missed in the smaller sample sizes (again ZERO toxicity).
What we have with CVM
I have posted many times that a drug like MK with ZERO TOXICITY treating a high mortality cancer illness should have received some type of conditional approval after the trial results were published. The FDA is a corrupt organization and Geert has shown nothing but continued ineptness in guiding this company. I dont understand why that there have been no shareholder lawsuits
MK will never be approved by FDA until CVM is bought out at fire sale and then MK submitted by big pharmaceutical company player. It could be insiders aren’t buying bc deal is on table. If CVM was a serious company Geert would have been fired long ago.
I can’t believe there are people on this board still supporting Geert. I do not understand how he has lasted this long. A drug like MK showing ZERO TOXICITY should have gotten some type of approval based on the improvement in 5 yr survival in the original study. PFE or BMY will buy this company in a fire sale and you will see some type of approval within 90 days after the takeover. I guess some of you traders will be happy with $20/s for a company worth 10x that as a standalone.
I think that we can all agree that you can be a bull on CVM but the “Geert morning” has to stop. He is inept at best and probably corrupt. MK had been around for over 30 years and still no approval or offers. Not even rumors. How a CEO can persist through all of this failure is hard to comprehend. So please, let’s just ban ‘Geert’ from the board. Even if it gets approved tomorrow, it is at least 15 years than a real CEO would have done.
I have been a huge believer in MK but have had little faith in Geert. It looks like bad management will overcome good science and drive CVM shares to ZERO.
The positive news is out there as the stock continues to crater. Would love some positive thoughts here other than cheerleading.
This is a waiting game. Can Merck (or whoever)use their hold over regulatory agencies (esp the horribly corrupt FDA) to bleed CVM of cash and force a sale at a bargain price? This is the endgame here. MK has clear value but the company has no clout and an inept CEO.
Should have been approved long ago.
Investors will do well even at $25 but as a standalone the company is probably worth $150 with approval. As you saw with the COVID vax , the FDA is a wholly owned subsidiary of big pharma
One has to think that there has to be reasonable expectation of approval to incur the expense of increasing the manufacturing facility. Somebody somewhere feels there is approval on the horizon. Again, I think this is a stall from the FDA servicing a big pharma company hoping to buy them out in a distress sale.
At this point I would hope we see some kind of takeover bid. Biotech companies being bought with rare disease portfolios. H&N cancer is a huge addressable market
I do not understand the pediatric waiver as MK is for an ADULT disease. Any pediatric applicatons would come after approval as oncologists wish to try on pediatric solid tumors. Again, I do not have faith in Geert. This is all taking WAY too long.
Let’s face it. The FDA is controlled by big pharma and they are not going to let a nothing company like $CVM bring a blockbuster cancer therapy to market. I used to treat H&N cancer. MK should have been approved long ago (proven efficacy- ZERO toxicity) if not for its inept/corrupt (what’s the difference) CEO. Patience will be rewarded , but likely with acquisition at $30-$40 dollars instead of $150-$200/s an independent $CVM would bring.
Let’s face it. We have invested in a company with an inept - perhaps corrupt - CEO. Why no shareholder update? Why no explanation regarding presence - or lack thereof - at JPM Health Conference? Remember the years wasted by poor oversight of company overseeing testing during early part of patient trials. Yes, testing company sued but YEARS wasted. Just one stumble/delay after another with no accountability to shareholders.
Saw Amgen CEO on Cramer. Why does small cell cancer drug gets ‘breakthrough therapy’ designation but Mk - with efficacy and ZERO toxicity - get ignored. Is it all about money with the FDA or perhaps they have a real CEO. No way at this point should Geert not have someone’s ear at the JPM Healthcare Conference. I have known about MK since 1990. This has all taken way too long. MK, cancer patients and investors deserve much better.